|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry显示文摘瞄准:为颜色检测新浆液简历标记由浆液蛋白质与提高表面的激光解吸附作用 ionisation 介绍的表面的癌症(CRC )-- 飞行团分光术(SELDI-TOF MS ) 的时间。方法:二个独立浆液样品集合与 ProteinChip 技术独立被分析(集合 A:40 CRC+49 健康控制;集合 B:37 CRC+31 健康控制) ,有一个弱阳离子的使用的芯片交换一半和缓冲区 pH 5。差别的歧视的力量表示了蛋白质与一个分类树算法被估计。产生分类树的敏感和特性被盲目地从集合 B 并且反过来也如此从集合 A 把数据用于产生的树获得。CRC 浆液蛋白质侧面也与从胸的那些相比,卵巢,前列腺,和非小的房间肺癌症。结果:Mass-to-charge 比率(m/z ) 3.1x10 (3 ) , 3.3x10 (3 ) , 4.5x10 (3 ) , 6.6x10 (3 ) 和 28x10 (3 ) 在最好执行的分类树上被用作分类器。树敏感和特性在 65% 和 90% 之间。大多数这些歧视的 m/z 价值在调查的另外的瘤类型也是不同的。M/z 3.3x10 (3 ) ,在大多数树上的主要分类器,是 6.6x10 (3 ) 的一种二倍地控告的形式 -Da 蛋白质。后者作为 apolipoprotein C-I 被识别。M/z 3.1x10 (3 ) 作为 apolipoprotein A-I 作为白朊,和 m/z 28x10 (3 ) 的 N 终端碎片被识别。结论:分类树模式分析跟随的 SELDI-TOF MS 是为为 CRC 发现新浆液标记的一种合适的技术。Biomarkers 能与高敏感和特性在独立样品集合被识别并且 reproducibly 检测了。尽管为 CRC 不特定,这些简历标记在监视的疾病和治疗有一个潜在的角色。 | Judith YMN Engwegen Helgi H Helgason Annemieke Cats Nathan Harris Johannes MG Bonfrer Jan HM Schellens Jos H Beijnen | 2006 | World Journal of Gastroenterology2006，12，10： | 45 |
| 2 | Simplified thermal and hygric building models: A literature review显示文摘 | Rick Kramer Jos van Schijndel Henk Schellen | 2012 | Frontiers of Architectural Research2012，1，4： | 3 |
| 3 | Population pharmacokinetic and dynamic analysis of the topoisomerase Ⅰ inhibitor lutotecan in phase Ⅱ studies显示文摘 | Schellens JHM Heinrich B Lehnert M | 2002 | Invest New Drugs2002，20，： | 2 |
| 4 | Intravenous - to -oral switch in anticancer chemotherapy:a focus on do- eetaxel and paclitaxel 显示文摘 | Koolen S L Beijnen J H Schellens J H | 2010 | Clin Pharmacol Ther2010，87，1： | 1 |
| 5 | The SHARON process: an innovative method for nitrogen removal from ammonium-rich wastewater显示文摘 | Hellinga C Schellen A A J C Mulder J W | 1998 | Water Science and Technology1998，37，9： | 1 |
| 6 | Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers显示文摘 | M. Joerger T. M. Bosch V. D. Doodeman J. H. Beijnen P. H. M. Smits J. H. M. Schellens | 2006 | European Journal of Clinical Pharmacology2006，，8： | 1 |
| 7 | Viral replication capacity as a correlate of HLA-B57/B5801-associated nonprogressive HIV-1 infection显示文摘 | Navis M Schellens I van Baarle D | 2007 | J Immunol2007，179，5： | 1 |
| 8 | The SHARON process: An innovative method for nitrogen removal from ammonium- rich waste water显示文摘 | Hellinga C Schellen A A J C Mulder J W | 1998 | Water Science and T~mology1998，37，9： | 1 |
| 9 | The Sharon-process: an innovative method for nitrogen removal form ammonium rich wastewater显示文摘 | Hellinga C Schellen A A J C Mulder J W | 1998 | Water Science and Technology1998，37，9： | 1 |
| 10 | Comparing the old and new generation SELDI-TOF MS : implications for serum protein profiling 显示文摘 | Gast MC Engwegen JY Schellens JH | 2008 | BMC Med Genomics2008，1，： | 1 |
| 11 | Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry 显示文摘 | ENGWEGEN J Y GAST M C SCHELLENS J H | 2006 | Trern Pharmacol Sci2006，27，5： | 1 |
| 12 | The SHARON process: an innovate method for nitrogen removal from ammoniumrich wastewater显示文摘 | Hellinga C Schellen AAJ C Mulder JW | 1998 | Water Science and Technology1998，37，9： | 1 |
| 13 | Generic solid phase extraction-liquid chromatography-tandem mass spectrometry method for fast determination of drugs in bio-logical fluids显示文摘 | Schellen A Ooms B van de Lagemaat D | 2003 | J Chromatogr B2003，788，2： | 1 |
| 14 | A ocktail'strategy to assess in vivo oxidative drug metabolism in humans 显示文摘 | BREIMER DD SCHELLENS JH | 1990 | Trends Pharmaeol Sei1990，11，6： | 1 |
| 15 | Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin显示文摘 | Zandvliet As Schellens JH Dittrich C | 2008 | Br J Clin Pharmacol2008，66，4： | 1 |
| 16 | Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours显示文摘 | VINK S R SCHELLENS J H BEIJNEN J H | 2006 | Radiother Oncol2006，80，2： | 1 |
| 17 | UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer显示文摘 | Ravaud A Borner M Schellens J H | 2001 | Eur J Cancer2001，37，13： | 1 |
| 18 | Clinical experience with aurora kinaseinhibitors:Areview显示文摘 | BOSS D S BEIJNEN J H SCHELLENS J H M | | Oncologist0，14，8： | 1 |
| 19 | Respiratorysyncytial virus inhibits granulocyte apoptosis through aphosphatidylinositol 3 -kinase and NF-kappaB-dependentmechanism 显示文摘 | Lindemans CA Coffer PJ Schellens IM | 2006 | J Immunol2006，176，： | 1 |
| 20 | Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs显示文摘 | Breedveld P Benjnen JH Schellens JHM | 2006 | Trends Pharmacol Sci2006，27，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员